Search Results 171-180 of 16999 for what is vedolizumab

1. A Study to Evaluate the Safety and Effectiveness of Ustekinumab as Initial or Maintenance Therapy for Patients with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

   ... vedolizumab at a dose approved for the treatment of UC and failed to respond to or tolerate such treatment; Is naïve to biologic therapy (TNF antagonists or ...

2. Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis - Mayo Clinic

   ... ulcerative colitis (UC). Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or ...

3. Pseudomembranous colitis - Symptoms & causes - Mayo Clinic

   Certain diseases that affect the colon, such as ulcerative colitis or Crohn's disease, also may put people at risk of pseudomembranous colitis. C. difficile ...

4. Ustekinumab-ttwe (intravenous route, subcutaneous route) - Mayo Clinic

   Ustekinumab-ttwe injection is also used to treat moderate to severe active Crohn's disease and ulcerative colitis. This medicine is available only with your ...

5. A Study to Identify Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease - Mayo Clinic

   A Study to Identify Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease · Overview · Participation eligibility · Participating Mayo Clinic locations.

6. A Study of the Relationship Between Infliximab Levels and the Rate of Colectomies in Patients who have Ulcerative Colitis - Mayo Clinic

   The purpose of this study is to assess if infliximab drug levels in patients who have Ulcerative Colitis predict the risk of needing a colectomy. Additionally, ...

7. Ustekinumab-srlf (intravenous route, subcutaneous route) - Mayo Clinic

   Ustekinumab-srlf injection is also used to treat moderate to severe active Crohn's disease and ulcerative colitis. This medicine is available only with your ...

8. A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment - Mayo Clinic

   A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment.

9. A Study to Evaluate Effectiveness and Safety of TD-1473 in Ulcerative Colitis - Mayo Clinic

   ... ulcerative colitis with up to 60 weeks of treatment. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and ...

10. A Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's Disease - Mayo Clinic

    Clinical Trials · A Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients with Moderately to Severely Active Crohn's ...